BioSpace News Archive

Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised $123 million in Series B financing

We are very impressed by our employees and partners for their resilience and achievements during 2020.

-U.S. Food and Drug Administration (FDA) filing of a Biologics License Application (BLA) and Priority Review for teplizumab for the delay or prevention of clinical type 1 diabetes in at-risk individuals; PDUFA goal date of July 2, 2021-

ESSA Pharma Inc. (Nasdaq: EPIX) ), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical collaboration and supply agreement with Astellas Pharma

CTP-543 Phase 3 Program Advancing in Alopecia Areata; THRIVE-AA2, the Second CTP‑543 Phase 3 Trial, to Initiate 1H2021 CTP-543 Long-Term Data Presented at EADV Show Hair Regrowth was Maintained or Improved in Patients with Alopecia Areata, Expanding Previous Phase 2 Results Conference Call and Webcast Scheduled Today at 8:30 a.m. ET

ReForm Biologics today announced it will expand its focus to develop a new generation of bio-innovative biologic medicines in-house to improve patient access, safety and convenience. As well, James (Jim) Sherblom has joined the board of directors of ReForm as chairman to lead the shift in strategy.

New venture is led by the former AveXis management team and was created in collaboration with Deerfield Management, which funded the Series A financing and provides access to established academic institutions for future pipeline programs The current pipeline utilizes the proven and well-characterized AAV9 vector to target diseases with significant unmet need, including galactosemia, genetic causes of autism spectrum disorder

AVROBIO to Present at Three Upcoming Investor Conferences in March

— Achieved Favorable Clinical Results Across Four First-in-Class Gene Therapy Programs for Danon Disease, FA, LAD-I and PKD — — Announced >50% Protein Expression with Stabilization and Biomarker Improvement Including Cardiac Output in Low Dose Cohort for Danon Disease Heart Failure Program —

Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune, or metabolic disorders, today announced the appointment of four vice presidents in areas of strategic importance for the company.